Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Other

Advenchen Laboratories Nanjing Ltd

Fei Liu

Xiquan Zhang

Hongjiang Xu

Yizhong Zhu

Yanlong Liu

Rui Zhao

Song Tang

Xin Tian

Shanchun Wang

Zhilin Chen

Hongmei Gu

Weiwei Feng

Ticong Huang

Ling Yang

Xiaojin Wang

Ting Wang

Wei Huang

Charles Z Ding

Lin Zhang

Na Zhao

Yan Zhu

Dan Li

Yinghui Sun

Hongjian Wang

Xijie Liu

Chunli Shen

Yanqing Yang

Ping Dong

Lulu Wang

Jianqing Zhang

Bin Wang

Huihui Zhang

Xujing Tang

Jianqiu Tang

Jinan Wang

Zhongyuan Hu

Hongying Zhang

Jingli Wu

Wei Wei

Huifeng Xiao

Wei Shi

Xiaobing Yan

Fansheng Kong

Liguang Dai

Jiahu Wu

Xiaowei Duan

Xinlu Li

Chuanyu Zhang

Limin Yang

Shenglin Chen

Ming Zhang

Feng Gong

Wenjun Geng

Yang Li

Limin Liu

Wenyuan Qian

Yahui Guo

Lei Xing

Yiyan Yao

Quandeng Nie

Yubing Wang

Haishan Zang

Jiuqing Zhang

Yuing Guo

Shanliang Zhu

Bo Zhu

Chao Gao

Bo Jiang

Jinfeng Jiang

Yayu Zhang

Yan Peng

Jie Zhou

Shibo Zhang

Huanqing Zhang

Hongjuan Li

Hao Zhou

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

The present application belongs to the field of medicine, and in particular relates to a crystal of a diarylthiohydantoin compound, a preparation method therefor, and use thereof in the preparation of medicaments for treating related diseases which are androgen-mediated.

Crystal of diarylthiohydantoin compound

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor

Provided is a salt of an Syk inhibitor and a crystalline form thereof, and more specifically, provided are 5-fluoro-1-methyl-3-((5-(4-(oxetan-3-yl)piperazine-1)-yl)pyridin-2-yl)amino)-6-(1H-pyrazol-3-yl)quinoline-2(1H)-ketamine hydrochloride, a crystalline form thereof, a preparation method therefor, a pharmaceutical composition thereof and a use thereof. The hydrochloride of the compound represented by formula I and the crystalline form thereof have good salt-forming properties, high stability and low hygroscopicity, have advantages in terms of physical properties, safety and metabolic stability, and have value in prepared medicines.

Salt of Syk inhibitor and crystalline form thereof

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine

The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.

Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk. 

Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer. 

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt

Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor. 

Crystal of salt of quinazoline derivative

Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease. 

M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof

Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a compound of formula V as a raw material. 

Method for preparing intermediate of 6-arylaminopyridonecarboxamide compound as MEK inhibitor

The present invention belongs to the field of drug crystals, relates to crystals of thiadiazole derivative DPP-IV inhibitors, and in particular relates to A and B type crystals of the compound as shown in formula 7. The crystals of the present invention have excellent stability. For example, under high temperature, high humidity or light test conditions, the material contents associated with the crystal of the compound of formula 7 do not change significantly. In addition, the crystal of the present invention also has a very good powder flowability and satisfies the requirements of drug preparation and production. 

Crystals of thiadiazole derivative DPP-IV inhibitors and uses thereof

The disclosure relates to a crystal of an aniline pyrimidine compound of trifluoroethyl substituted indole and a salt thereof as an EGFR inhibitor, specifically relates to a crystal of a compound represented by formula I, a crystal of monomethyl sulfonate of the compound represented by formula I or a crystal of dimethyl sulfonate of the compound represented by formula I, and further relates to a method for preparing the crystal, a crystalline composition comprising the crystal, or a pharmaceutical composition comprising the crystal or a crystalline composition thereof, and a medical use thereof. 

Crystal of aniline pyrimidine compound of trifluoroethyl substituted indole and salt thereof

The present application relates to maleates of a compound of Formula I, methods for preparing the same, pharmaceutical compositions thereof and uses thereof in the treatment of tumors, such as non-small cell lung cancer, breast cancer, and other malignant tumors. 

Salts of quinazoline derivative and method for preparing the same

Growing community of inventors

Lianyungang, China

Fei Liu